DE69531939D1 - Palladium katalysierter ringschluss von triazolyl-tryptamin - Google Patents

Palladium katalysierter ringschluss von triazolyl-tryptamin

Info

Publication number
DE69531939D1
DE69531939D1 DE69531939T DE69531939T DE69531939D1 DE 69531939 D1 DE69531939 D1 DE 69531939D1 DE 69531939 T DE69531939 T DE 69531939T DE 69531939 T DE69531939 T DE 69531939T DE 69531939 D1 DE69531939 D1 DE 69531939D1
Authority
DE
Germany
Prior art keywords
tryptamine
triazolyl
catalyzed ring
palladium catalyzed
ring close
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531939T
Other languages
English (en)
Other versions
DE69531939T2 (de
Inventor
Y Chen
D Larsen
R Verhoeven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69531939D1 publication Critical patent/DE69531939D1/de
Application granted granted Critical
Publication of DE69531939T2 publication Critical patent/DE69531939T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Inorganic Insulating Materials (AREA)
DE69531939T 1994-05-24 1995-05-19 Palladium katalysierter ringschluss von triazolyl-tryptamin Expired - Lifetime DE69531939T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine
US248288 1994-05-24
PCT/US1995/005506 WO1995032197A1 (en) 1994-05-24 1995-05-19 Palladium catalyzed ring closure of triazolyl tryptamine

Publications (2)

Publication Number Publication Date
DE69531939D1 true DE69531939D1 (de) 2003-11-20
DE69531939T2 DE69531939T2 (de) 2004-07-29

Family

ID=22938473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531939T Expired - Lifetime DE69531939T2 (de) 1994-05-24 1995-05-19 Palladium katalysierter ringschluss von triazolyl-tryptamin

Country Status (24)

Country Link
US (1) US5567824A (de)
EP (1) EP0763032B1 (de)
JP (1) JP3947216B2 (de)
KR (1) KR100385027B1 (de)
CN (2) CN1077104C (de)
AT (1) ATE252095T1 (de)
AU (1) AU688505B2 (de)
DE (1) DE69531939T2 (de)
DK (1) DK0763032T3 (de)
ES (1) ES2207648T3 (de)
FI (1) FI116899B (de)
HK (2) HK1009045A1 (de)
HR (1) HRP950304B1 (de)
HU (1) HU226460B1 (de)
MX (1) MX9605838A (de)
NZ (1) NZ285539A (de)
PT (1) PT763032E (de)
RO (1) RO118586B1 (de)
RU (1) RU2138496C1 (de)
SK (1) SK284495B6 (de)
TW (1) TW300221B (de)
UA (1) UA52586C2 (de)
WO (1) WO1995032197A1 (de)
YU (1) YU49345B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
DE69616335T2 (de) * 1995-07-11 2002-07-11 Merck & Co Inc Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
AU4053497A (en) * 1996-08-13 1998-03-06 Merck & Co., Inc. Palladium catalyzed indolization
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
EE04592B1 (et) * 1999-06-28 2006-02-15 Janssen Pharmaceutica N.V. Respiratoorse süntsütiaalviiruse replikatsiooni inhibiitorid, nende valmistamismeetod, kasutamine ja vaheühendid, farmatseutiline kompositsioon ja selle valmistamismeetod ning produkt
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
CA2552663A1 (en) * 2004-01-09 2005-07-28 Ratiopharm Gmbh Crystalline forms of rizatriptan benzoate
DK1751104T3 (da) 2004-01-28 2010-06-07 Ratiopharm Gmbh Syntesemetoder og mellemprodukter til fremstilling af rizatriptan
PA8626701A1 (es) * 2004-03-26 2006-05-16 Wyeth Corp Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
EP1951713A1 (de) * 2005-11-14 2008-08-06 Matrix Laboratories Ltd Verfahren zur herstellung von rizatriptanbenzoat im grossmasstab
EP1981860B1 (de) * 2006-01-19 2011-05-25 Matrix Laboratories Ltd Umwandlung eines aromatischen diazoniumsalzes in ein arylhydrazin
EP2160390A1 (de) * 2007-06-04 2010-03-10 Generics Ýuk¨Limited Neues verfahren
EP3407869A1 (de) 2016-01-27 2018-12-05 Instar Technologies A.S. Oromucosale nanofaserträger zur therapeutischen behandlung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
KR100385027B1 (ko) 2003-08-14
NZ285539A (en) 1998-06-26
AU688505B2 (en) 1998-03-12
FI964669A (fi) 1996-11-22
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
FI116899B (fi) 2006-03-31
EP0763032B1 (de) 2003-10-15
AU2467195A (en) 1995-12-18
YU49345B (sh) 2005-07-19
HK1041262A1 (en) 2002-07-05
DK0763032T3 (da) 2004-02-09
HK1009045A1 (en) 1999-05-21
HU9603236D0 (en) 1997-01-28
CN1157390C (zh) 2004-07-14
ATE252095T1 (de) 2003-11-15
HK1041262B (zh) 2005-04-15
HRP950304A2 (en) 1997-08-31
JPH10500680A (ja) 1998-01-20
SK149896A3 (en) 1997-09-10
WO1995032197A1 (en) 1995-11-30
SK284495B6 (sk) 2005-05-05
CN1152920A (zh) 1997-06-25
ES2207648T3 (es) 2004-06-01
RO118586B1 (ro) 2003-07-30
US5567824A (en) 1996-10-22
EP0763032A1 (de) 1997-03-19
FI964669A0 (fi) 1996-11-22
PT763032E (pt) 2004-02-27
JP3947216B2 (ja) 2007-07-18
HRP950304B1 (en) 2004-12-31
MX9605838A (es) 1997-12-31
CN1077104C (zh) 2002-01-02
TW300221B (de) 1997-03-11
YU33495A (sh) 1998-07-10
DE69531939T2 (de) 2004-07-29
HUT76469A (en) 1997-09-29
CN1322725A (zh) 2001-11-21
HU226460B1 (en) 2008-12-29
KR970703336A (ko) 1997-07-03

Similar Documents

Publication Publication Date Title
DE69531939D1 (de) Palladium katalysierter ringschluss von triazolyl-tryptamin
DE69413542D1 (de) Perhydroisoindolderivate als substanz p antagonisten
TR199802156T2 (xx) �kameli s�lfinil heteroksiklilin magnezyum tuzunun haz�rlanmas� i�lemi.
DE69922703D1 (de) Ureido-thiobuttersäurederivate als ppar-agonisten
EA200000393A1 (ru) Химические соединения
FI873631A (fi) --alkyl-4-amino-3-kinolinmetanoler och 1-(4-aralkylamino-3-kinolinyl)alkanoler, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
PT74626B (en) Process for preparing 9-<2-(3-indolyl)ethyl>-1-oxa-4,9-diazas- piro<5,5>undecan-3-ones
ATE275545T1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
ATE48835T1 (de) Chinolylglycinamidderivate, verfahren zu ihrer herstellung und therapeutische verwendung als psychotrope.
KR840004746A (ko) 2-옥소-1-아제티딘술폰산 유도체의 제조방법
DE69807073D1 (de) Herstellung von tri-iodo-benzol-verbindungen
JPS5359663A (en) 2-halogeno methyl indole derivatives and process for praparation of the same
CA2190851A1 (en) Palladium catalyzed ring closure of triazolyl tryptamine
DE69906243D1 (de) 2-Indanmethanolderivate und ihre Verwendung als Riechstoffe
DK432086D0 (da) Fremgangsmaade til fremstilling af beta-lactamforbindelser eller saltederaf
KR840001974A (ko) 1-[3-(6-플루오로-1,2-벤즈이속사졸-3-일)프로필]-4-(치환된)-피페라진 및-피레리딘의 제조방법
ES8407042A1 (es) Procedimiento para la obtencion de un nuevo derivado del sulpiride.
JPH0356452A (ja) 安息香酸誘導体の製造方法
KR970042548A (ko) 이미다조 피리딘 유도체,이의 제조방법 및 이를 함유한 약제학적 조성물
IT1270017B (it) "sintesi quantitativa dell'acido 3-(l-piroglutamil)-l-tiazolidin-4- carbossilico e suoi derivati"
JPS54106498A (en) Carbostyril derivative
GB9815481D0 (en) Pharmaceuticals
DK0557519T3 (da) Fremgangsmåde til fremstilling af sulfonamidderivater af norbornan
JPS5640677A (en) Catechol derivative and its preparation
JPS5566562A (en) Novel imidazole derivative and antidepressant containing the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 763032

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 763032

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213